Posted by Michael Wonder on 31 Jan 2023
Medicare drug price negotiation in the United States: implications and unanswered questions
8 December 2022 - The United States is a relatively free pricing market for pharmaceutical manufacturers to set list prices at the product launch.
Few drug price controls exist, and federal price negotiation as a policy has historically been politically untenable.
After decades of debate on whether the federal government, specifically the Medicare program, should more actively manage drug prices, the US Congress passed legislation authorising Medicare to directly negotiate prices with manufacturers.
